The safety and pharmacokinetics of ABI-4334, a novel next-generation HBV core inhibitor: interim results from a phase 1 study in healthy volunteers

被引：0

作者：

Gane, Edward J. ^{[1
]}

Schwabe, Christian ^{[2
]}

Liu, Jieming ^{[3
]}

Stamm, Luisa M. ^{[3
]}

Kitrinos, Kathryn M. ^{[3
]}

Knox, Steven J. ^{[3
]}

Anderson, Michele ^{[3
]}

Wang, Grace ^{[3
]}

Zomorodi, Katie ^{[3
]}

机构：

[1] Univ Auckland, Auckland, New Zealand

[2] New Zealand Clin Res, Auckland, New Zealand

[3] Assembly Biosci, San Francisco, CA USA

来源：

JOURNAL OF HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

SAT-186

引用

页码：S1161 / S1162

页数：2

共 50 条

[21] Interim safety, tolerability pharmacokinetics, and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers and non-cirrhotic viremic subjects with chronic hepatitis B
Yuen, M. -F.
Agarwal, K.
Gane, E.
Schwabe, C.
Cheng, W.
Sievert, W.
Kim, D. J.
Ahn, S. H.
Lim, Y. -S.
Visvanathan, K.
Ruby, E.
Liaw, S.
Colonno, R.
Lopatin, U.
JOURNAL OF HEPATOLOGY, 2018, 68 : S111 - S111
[22] Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers
Freeman, Mason W.
Bond, Mary
Murphy, Brian
Hui, James
Isaacsohn, Jonathan
HYPERTENSION RESEARCH, 2023, 46 (01) : 108 - 118
[23] Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers
Mason W. Freeman
Mary Bond
Brian Murphy
James Hui
Jonathan Isaacsohn
Hypertension Research, 2023, 46 : 108 - 118
[24] Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 study
Agarwal, Kosh
Xu, Jia
Gane, Edward J.
Nguyen, Tuan T.
Ding, Yanhua
Knox, Steven J.
Alves, Katia
Evanchik, Marc
Zomorodi, Katie
Ma, Julie
Yan, Ran
Huang, Qi
Colonno, Richard
Stamm, Luisa M.
Hassanein, Tarek I.
Kim, Dong Joon
Lim, Young-Suk
Yuen, Man-Fung
JOURNAL OF VIRAL HEPATITIS, 2023, 30 (03) : 209 - 222
[25] Safety and Pharmacokinetics of Single-Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study
Xu, Junyu
Xie, Ran
Ji, Yongjia
Qian, Chenxi
Zhang, Xin
Todd, Kris
Wang, Feng
Cui, Yimin
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (10): : 1143 - 1150
[26] Initial Results of a Phase 1 Dose Escalation Study of LP-168, a Novel Covalent and NonCovalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase
Woyach, Jennifer A.
Stephens, Deborah M.
Brander, Danielle M.
Kittai, Adam S.
Hu, Boyu
Sitlinger, Andrea
Curran, Emily K.
Tan, Fenlai
Chen, Yi
Anthony, Stephen P.
Chen, Yu
Byrd, John C.
BLOOD, 2023, 142
[27] Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers
Kansagra, Kevinkumar A.
Parmar, Deven
Jani, Rajendra H.
Srinivas, Nuggehally R.
Lickliter, Jason
Patel, Harilal V.
Parikh, Devang P.
Heading, Heather
Patel, Hardik B.
Gupta, Rahul J.
Shah, Chintan Y.
Patel, Maulik R.
Dholakia, Vyom N.
Sukhadiya, Raghav
Jain, Mukul R.
Parmar, Krupi V.
Barot, Kinjal
CLINICAL PHARMACOKINETICS, 2018, 57 (01) : 87 - 102
[28] Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers
Kevinkumar A. Kansagra
Deven Parmar
Rajendra H. Jani
Nuggehally R. Srinivas
Jason Lickliter
Harilal V. Patel
Devang P. Parikh
Heather Heading
Hardik B. Patel
Rahul J. Gupta
Chintan Y. Shah
Maulik R. Patel
Vyom N. Dholakia
Raghav Sukhadiya
Mukul R. Jain
Krupi V. Parmar
Kinjal Barot
Clinical Pharmacokinetics, 2018, 57 : 87 - 102
[29] Safety, tolerability, pharmacokinetics(PK) and pharmacodynamics(PD) of HSK31858,a novel DPP-1 inhibitor in healthy volunteers:a phase I clinical trial
Hou, Jie
Guan, Wei Jie
Li, Fang Qiong
Zeng, Wei Fang
Liu, Han Mo
EUROPEAN RESPIRATORY JOURNAL, 2023, 62
[30] OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers
Bagger, Yu
Ravis, William R.
Harris, Geoff
Bukofzer, Stan
CLINICAL DRUG INVESTIGATION, 2023, 43 (09) : 709 - 717

← 1 2 3 4 5 →